Entries by Maren Kühr

Market trends and the biopharma evolution

With many complex factors affecting a therapeutic candidate’s chances of approval, partnering with a qualified service provider can be the most effective way to produce material for clinical trials. Outsourcing allows you to delay critical capacity decisions until the fate of your molecule is more certain — but, how do you ensure this approach results in a successful process that’s delivered within your target timeline?

Startup Labs at the Vienna BioCenter

The Vienna Business Agency has set up affordable and flexible Startup Labs at the Vienna BioCenter. This will speed up the evaluation and implementation of new business ideas in biotechnology by the next coming generation of bio-entrepreneurs. Key assets include close proximity to outstanding academic research and highly successful innovators as well as access to cutting-edge research infrastructure.

Searching for an effective treatment for COVID-19

Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.

A Comprehensive Tool Set for COVID-19 Research

Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.

Complete toolkit for SARS-CoV-2 antigen test

Sino Biological Inc. has developed a complete toolkit for SARS-CoV-2 antigen tests, including a large panel of antibodies specific to SARS-CoV-2 S&N proteins and antibody pairs that can be used to assemble detection assays for the corresponding antigen.

Antiviral drugs for pandemic preparedness

Viral pandemics are not a once-in-a-lifetime event but a constant threat looming over our heads. While the fight against SARS-CoV-2 is currently a top priority, we should not lose sight of what might come next. Broad-spectrum antiviral drugs like Atriva’s ATR-002, currently in Phase II clinical development for treating COVID-19, could be an effective measure in the fight against the current pandemic and future viral outbreaks.

Interview: How to improve data analytics

Interview with Ian Harrow from the Pistoia Alliance, about how to improve life sciences data management with help of a new digital toolkit that makes data Findable, Accessible, Interoperable, and Reusable – in brief: FAIR.